Serial verb constructions and the syntax-prosody interface
Natural Language & Linguistic Theory · 2022-02 · 40 (1) · 285-306
DOI: 10.1007/s11049-021-09507-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Natural Language & Linguistic Theory, 2022-02. Verfasst von Matthew Tyler und 1 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Rolle (2020) identifies an apparent morphophonological conspiracy in serial verb constructions (SVCs) in Degema. He argues that it constitutes evidence for a partly-unified postsyntactic module, in which morphology and prosody are built in parallel (by ‘Optimality-Theoretic Distributed Morphology’). We argue that the pattern Rolle identifies in Degema SVCs instead results from the simultaneous interaction of two independently-attested syntax-prosody phenomena: (1) the pressure for adjacent verbs in an SVC to form a single prosodic unit, and (2) the suppression of redundant agreement within a single prosodic word (a.k.a. ‘Kinyalolo’s Generalization’). Thus the Degema SVC conspiracy can be localized to the syntax-prosody interface, and there is no need to adopt a unified postsyntactic morphology-prosody module like Rolle’s. We offer some further conceptual critiques of his model.
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Tyler, M., & Kastner, I. (2022). Serial verb constructions and the syntax-prosody interface. Natural Language & Linguistic Theory. https://doi.org/10.1007/s11049-021-09507-0
Vancouver
Tyler M, Kastner I. Serial verb constructions and the syntax-prosody interface. Natural Language & Linguistic Theory. 2022. doi:10.1007/s11049-021-09507-0
BibTeX
@article{Tyler2022,
author = {Tyler, Matthew and Kastner, Itamar},
title = {Serial verb constructions and the syntax-prosody interface},
journal = {Natural Language & Linguistic Theory},
year = {2022},
doi = {10.1007/s11049-021-09507-0}
}
EUVIMED